THERAPY DOSSIER · th-45cbc0793cec

LR12, a synthetic TREM-1 inhibitory peptide

Drug · Triggering receptor expressed on myeloid cells 1 (TREM-1) inhibitor; action type INHIBITOR, direct interaction, disease efficacy flagged (ChEMBL mec_id 8579).

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: Triggering receptor expressed on myeloid cells 1 (TREM-1) inhibitor; action type INHIBITOR, direct interaction, disease efficacy flagged (ChEMBL mec_id 8579).
Target: CHEMBL1697674 (TREM-1)
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL4297793 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: LR-12; LR12; Motrem; Nangibotide; Nangibotida
Note: Not recorded

Clinical trials 4

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03158948 ↗PHASE2completed

Safety, tolerability, PK and PD of three doses of MOTREM (nangibotide) in patients with septic shock

Septic Shock

Enrolment: 50 · Results not recorded

NCT04429334 ↗PHASE2completed

ESSENTIAL: nangibotide in COVID-19 patients with ventilatory support

COVID-19

Enrolment: 220 · Results not recorded

NCT04055909 ↗PHASE2active not recruiting

Efficacy, safety and tolerability of nangibotide in patients with septic shock (dose selection)

Septic Shock

Enrolment: 355 · Results not recorded

NCT03463044 ↗PHASE1completed

Phase I ascending single intravenous doses of MOTREM (LR12) in healthy male subjects

Healthy Subjects

Enrolment: 27 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25840803 ↗2015Reported benefit

TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction.

MixedIschaemia-reperfusionCardiacC57BL/6 mice including Trem-1 knockout mice; Wistar ratsmalen = n=20-22 per group for survival and left ventricular functio…

Model: Myocardial infarction from permanent and transient coronary ischaemia; parallel human cohort with acute myocardial infarction

TREM-1 was upregulated in ischaemic myocardium in mice and humans. Trem-1 genetic invalidation or pharmacological inhibition with LR12 dampened myocardial inflammation, limited neutrophil recruitment and MCP-1 production, reduced classical monocyte mobilisation, and improved left ventricular functi…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…